During the past decade, Josephson Wallack Munshower Neurology PC conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 24 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 16 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Josephson Wallack Munshower Neurology PC" #1 sponsor was "Eli Lilly and Company" with 12 trials, followed by "Allergan" with 5 trials sponsored, "Biogen" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Josephson Wallack Munshower Neurology PC" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Chiltern International Inc." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "National Institute on Aging (NIA)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Josephson Wallack Munshower Neurology PC" are "Alzheimer Disease" (8 trials), "Alzheimer's Disease" (5 trials), "Migraine" (5 trials), "Multiple Sclerosis" (4 trials) and "Dopamine Beta Hydroxylase Deficiency" (2 trials). Many other conditions were trialed in "Josephson Wallack Munshower Neurology PC" in a lesser frequency.

Most popular intervention types in "Josephson Wallack Munshower Neurology PC" are "Drug" (47 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Donanemab" (4 trials), "Ocrelizumab" (4 trials), "Aducanumab" (3 trials) and "Atogepant" (2 trials). Other intervention names were less common.

The vast majority of trials in "Josephson Wallack Munshower Neurology PC" are 49 trials for "All" genders.

Currently, there are NaN active trials in "Josephson Wallack Munshower Neurology PC". undefined are not yet recruiting, 12 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Josephson Wallack Munshower Neurology PC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Josephson Wallack Munshower Neurology PC, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".